131 related articles for article (PubMed ID: 36044093)
1. Effect of intravenous ferric carboxymaltose on exercise capacity and quality of life in patients with COPD : A pilot study.
Grasmuk-Siegl E; Urban MH; Scherrer S; Funk GC
Wien Klin Wochenschr; 2023 Jan; 135(1-2):35-44. PubMed ID: 36044093
[TBL] [Abstract][Full Text] [Related]
2. Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial.
Santer P; McGahey A; Frise MC; Petousi N; Talbot NP; Baskerville R; Bafadhel M; Nickol AH; Robbins PA
BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32565444
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Iron Replacement Improves Exercise Tolerance in COPD: A Single-Blind Randomized Trial.
Martín-Ontiyuelo C; Rodó-Pin A; Echeverría-Esnal D; Admetlló M; Duran-Jordà X; Alvarado M; Gea J; Barreiro E; Rodríguez-Chiaradía DA
Arch Bronconeumol; 2022 Oct; 58(10):689-698. PubMed ID: 35312562
[TBL] [Abstract][Full Text] [Related]
4. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
5. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
6. Whole-body vibration improves functional capacity and quality of life in patients with severe chronic obstructive pulmonary disease (COPD): a pilot study.
Braz Júnior DS; Dornelas de Andrade A; Teixeira AS; Cavalcanti CA; Morais AB; Marinho PE
Int J Chron Obstruct Pulmon Dis; 2015; 10():125-32. PubMed ID: 25624756
[TBL] [Abstract][Full Text] [Related]
7. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
[TBL] [Abstract][Full Text] [Related]
8. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
[TBL] [Abstract][Full Text] [Related]
9. Effect of Intravenous Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial.
Vinke JS; Eisenga MF; Sanders JF; Berger SP; Spikman JM; Abdulahad WH; Bakker SJ; Gaillard CAJM; van Zuilen AD; van der Meer P; de Borst MH
BMJ Open; 2023 Mar; 13(3):e065423. PubMed ID: 36948568
[TBL] [Abstract][Full Text] [Related]
10. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A
J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835
[TBL] [Abstract][Full Text] [Related]
13. A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease.
Nickol AH; Frise MC; Cheng HY; McGahey A; McFadyen BM; Harris-Wright T; Bart NK; Curtis MK; Khandwala S; O'Neill DP; Pollard KA; Hardinge FM; Rahman NM; Armitage AE; Dorrington KL; Drakesmith H; Ratcliffe PJ; Robbins PA
BMJ Open; 2015 Jul; 5(7):e007911. PubMed ID: 26150144
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure.
Caravita S; Faini A; Vignati C; Pelucchi S; Salvioni E; Cattadori G; Baratto C; Torlasco C; Contini M; Villani A; Malfatto G; Perger E; Lombardi C; Piperno A; Agostoni P; Parati G
Eur J Heart Fail; 2022 Oct; 24(10):1940-1949. PubMed ID: 35867685
[TBL] [Abstract][Full Text] [Related]
15. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
[TBL] [Abstract][Full Text] [Related]
16. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status.
Bhandari S; Allgar V; Lamplugh A; Macdougall I; Kalra PA
BMC Nephrol; 2021 Mar; 22(1):115. PubMed ID: 33784968
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
18. Iron Deficiency in Heart Failure: An Overview.
von Haehling S; Ebner N; Evertz R; Ponikowski P; Anker SD
JACC Heart Fail; 2019 Jan; 7(1):36-46. PubMed ID: 30553903
[TBL] [Abstract][Full Text] [Related]
19. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial.
Vanobberghen F; Lweno O; Kuemmerle A; Mwebi KD; Asilia P; Issa A; Simon B; Mswata S; Schmidlin S; Glass TR; Abdulla S; Daubenberger C; Tanner M; Meyer-Monard S
Lancet Glob Health; 2021 Feb; 9(2):e189-e198. PubMed ID: 33245866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
